On this page

Nystop

Nystatin · Powder

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Nystop
Generic name
Nystatin
Dosage form
Powder
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
7
Packages
11
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 100000 [USP'U]/g 261178 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Powder
Route of administration
Topical
Presentations
18

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064118
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 16, 1996
Sponsor
PADAGIS US
Products on application
1
Submissions recorded
13
Products approved under application 064118.
Product Trade name Form Strength Ingredient Status TE Flags
064118-001 NYSTOP POWDER NYSTATIN Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064118.
Type No. Action Status Date Review
Supplement 12 Labeling Approved November 13, 2002 —
Supplement 11 Manufacturing (CMC) Approved November 13, 2002 —
Supplement 10 Labeling Approved September 8, 2000 —
Supplement 9 Manufacturing (CMC) Approved September 21, 1998 —
Supplement 8 Manufacturing (CMC) Approved September 21, 1998 —
Supplement 6 Manufacturing (CMC) Approved July 10, 1998 —
Supplement 5 Labeling Approved July 10, 1998 —
Supplement 4 Manufacturing (CMC) Approved July 10, 1998 —
Supplement 7 Manufacturing (CMC) Approved April 20, 1998 —
Supplement 3 Manufacturing (CMC) Approved July 30, 1997 —
Supplement 2 Manufacturing (CMC) Approved July 17, 1997 —
Supplement 1 Manufacturing (CMC) Approved February 10, 1997 —
Original application 1 Approved August 16, 1996 —

Review documents

  • 0 · Original application · July 22, 2005

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260714). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260714 HUMAN PRESCRIPTION DRUG · 20241031

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older): Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Nystatin Topical Powder is contraindicated in patients with a history of hypersensitivity to any of its components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General .)

Description

openFDA Drug Labeling

DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. The molecular formula for Nystatin is C 47 H 75 NO 17 . The molecular weight of Nystatin is 926.1. Structural formula: Nystatin Topical Powder USP is for dermatologic use. Nystatin Topical Powder USP contains 100,000 USP nystatin units per gram dispersed in talc. Structural Formula

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystop® Nystatin Topical Powder USP is supplied as 100,000 units nystatin per gram in 15 g, 30 g and 60 g plastic squeeze bottles. NDC: 72162-1124-2: 15 g in a BOTTLE NDC: 72162-1124-3: 30 g in a BOTTLE NDC: 72162-1124-6: 60 g in a BOTTLE STORAGE Store at controlled room temperature 15°-30°C (59°-86°F); avoid excessive heat (40°C; 104°F). Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
27,387
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8696-1 63629-8696 Bryant Ranch Prepack 15 g in 1 BOTTLE, PLASTIC (63629-8696-1) August 16, 1996
63629-8697-1 63629-8697 Bryant Ranch Prepack 30 g in 1 BOTTLE, PLASTIC (63629-8697-1) August 16, 1996
63629-8698-1 63629-8698 Bryant Ranch Prepack 60 g in 1 BOTTLE, PLASTIC (63629-8698-1) August 16, 1996
71335-2845-1 71335-2845 Bryant Ranch Prepack 15 g in 1 BOTTLE, PLASTIC (71335-2845-1) October 21, 2025
71335-2869-1 71335-2869 Bryant Ranch Prepack 30 g in 1 BOTTLE, PLASTIC (71335-2869-1) October 21, 2025
72162-1124-2 72162-1124 Bryant Ranch Prepack 15 g in 1 BOTTLE, PLASTIC (72162-1124-2) December 24, 2024
72162-1124-3 72162-1124 Bryant Ranch Prepack 30 g in 1 BOTTLE, PLASTIC (72162-1124-3) December 24, 2024
72162-1124-6 72162-1124 Bryant Ranch Prepack 60 g in 1 BOTTLE, PLASTIC (72162-1124-6) December 24, 2024
0574-2008-02 0574-2008 Padagis US LLC 60 g in 1 BOTTLE, PLASTIC (0574-2008-02) August 16, 1996
0574-2008-15 0574-2008 Padagis US LLC 15 g in 1 BOTTLE, PLASTIC (0574-2008-15) August 16, 1996
0574-2008-30 0574-2008 Padagis US LLC 30 g in 1 BOTTLE, PLASTIC (0574-2008-30) August 16, 1996
63629-8696 63629-8696 Bryant Ranch Prepack — August 16, 1996
63629-8697 63629-8697 Bryant Ranch Prepack — August 16, 1996
63629-8698 63629-8698 Bryant Ranch Prepack — August 16, 1996
71335-2845 71335-2845 Bryant Ranch Prepack — August 16, 1996
71335-2869 71335-2869 Bryant Ranch Prepack — August 16, 1996
72162-1124 72162-1124 Bryant Ranch Prepack — August 16, 1996
0574-2008 0574-2008 Padagis US LLC — August 16, 1996

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.